• Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects
  View in Chinese
  • Dabigatran
  • Apixaban
  • Summary and recommendations
  • Advantages and disadvantages of oral anticoagulants (Tables)
  • Coagulation cascade anticoagulant effects (Figures)
• Management of bleeding in patients receiving direct oral anticoagulants
  View in Chinese
  • Rivaroxaban, apixaban, edoxaban, betrixaban (reversal)
  • Summary and recommendations
• Atrial fibrillation: Anticoagulant therapy to prevent embolization
  View in Chinese
  • Select an anticoagulant
  • Dosing of non-vitamin K antagonist oral anticoagulants
  • Summary and recommendations
• Rationale and indications for indefinite anticoagulation in patients with venous thromboembolism
  View in Chinese
  • Terminology
  • Summary and recommendations
• Venous thromboembolism: Anticoagulation after initial management
  View in Chinese
  • Nomenclature
  • Summary and recommendations
• Perioperative management of patients receiving anticoagulants
  View in Chinese
  • Timing of anticoagulant interruption
  • Summary and recommendations
• Venous thromboembolism: Initiation of anticoagulation (first 10 days)
  View in Chinese
  • Nomenclature
  • Summary and recommendations
• Preoperative evaluation and perioperative strategies to minimize blood transfusion
  • Management of medications affecting hemostasis
  • Summary and recommendations
• Transcatheter aortic valve implantation: Complications
  • Valve thrombosis
  • Summary and recommendations
• Treatment of venous thromboembolism in patients with malignancy
  View in Chinese
  • Direct oral anticoagulants versus warfarin
  • Summary and recommendations
• Overview of the treatment of lower extremity deep vein thrombosis (DVT)
  View in Chinese
  • Nomenclature
  • Summary and recommendations
• Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease
  View in Chinese
  • Estimated glomerular filtration rate 30 to 59 mL/min/1.73 m2 (stage 3 CKD)
  • Estimated glomerular filtration rate between 15 and 29 mL/min/1.73 m2 (stage 4 CKD)
  • Summary and recommendations
• Risk of intracerebral bleeding in patients treated with anticoagulants
  View in Chinese
  • Dabigatran, rivaroxaban, apixaban
  • Summary and recommendations
• Prevention of venous thromboembolic disease in surgical patients
  View in Chinese
  • Pharmacologic agents for VTE prevention
  • Summary and recommendations
• Chronic anticoagulation after acute coronary syndromes
  View in Chinese
  • Patients without other indications for chronic anticoagulation
  • Summary and recommendations
• Klippel-Trenaunay syndrome: Clinical manifestations, diagnosis, and management
  View in Chinese
  • Summary and recommendations
• Catheter ablation to prevent recurrent atrial fibrillation: Anticoagulation
  View in Chinese
  • Choice of anticoagulant
  • Patients taking NOAC
  • Summary and recommendations
• Antithrombotic therapy for prosthetic heart valves: Indications
  View in Chinese
  • Oral direct thrombin inhibitors and factor Xa inhibitors
  • Summary and recommendations
• Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation
  View in Chinese
  • Anticoagulant approach
  • Before cardioversion
  • Summary and recommendations
• Antithrombotic therapy after coronary stenting in patients receiving long-term anticoagulation
  View in Chinese
  • Alternatives to warfarin
  • Summary and recommendations
• Anticoagulation in older adults
  View in Chinese
  • Warfarin versus other oral anticoagulants
  • Summary and recommendations
• What's new in hematology
  • Underdosing of direct oral anticoagulants (February 2017)
• Use of anticoagulants during pregnancy and postpartum
  View in Chinese
  • Anticoagulants that are generally avoided during pregnancy
  • Overview of anticoagulant choice
  • Summary and recommendations
• What's new in hospital medicine
  • Underdosing of direct oral anticoagulants (February 2017)
• What's new in pulmonary and critical care medicine
  • Underdosing of direct oral anticoagulants (February 2017)
• Hemodialysis anticoagulation
  View in Chinese
  • Non-warfarin oral anticoagulants
  • Summary and recommendations
• Stroke in patients with atrial fibrillation
  View in Chinese
  • Edoxaban
  • Apixaban
  • Summary
• What's new in primary care
  • Underdosing of direct oral anticoagulants (February 2017)
• Treatment of antiphospholipid syndrome
  View in Chinese
  • Target-specific oral anticoagulants
  • Summary and recommendations
• Antithrombin deficiency
  View in Chinese
  • Timing of testing
  • Summary and recommendations
• What's new in family medicine
  • Underdosing of direct oral anticoagulants (February 2017)
• Management and prognosis of Ebstein anomaly
  • Prophylaxis against thromboembolism
  • Summary and recommendations
• Management of anticoagulants in patients undergoing endoscopic procedures
  View in Chinese
  • High-risk procedures, low-risk conditions
  • Summary and recommendations
• Warfarin and other VKAs: Dosing and adverse effects
  View in Chinese
  • Transitioning between anticoagulants/bridging
  • Summary and recommendations
• Periprocedural management of antithrombotic therapy in patients receiving long-term oral anticoagulation undergoing percutaneous coronary intervention
  View in Chinese
  • Elective patients
  • Summary and recommendations
• Hypertrophic cardiomyopathy: Prevalence, pathophysiology, and management of concurrent atrial arrhythmias
  View in Chinese
  • Long-term management
  • Summary and recommendations
• Clinical use of coagulation tests
  View in Chinese
  • Prothrombin time (PT) and INR
  • Patient on anticoagulant
  • Summary and recommendations
• Fondaparinux: Dosing and adverse effects
  View in Chinese
  • Transitioning between anticoagulants
  • Summary and recommendations
• Management of heparin-induced thrombocytopenia
  View in Chinese
  • Other agents
  • Summary and recommendations
• What's new in cardiovascular medicine
  • Management of dabigatran in the periprocedural period prior to catheter ablation for AF (June 2017)
  • Rivaroxaban plus P2Y12 inhibitor in patients with atrial fibrillation who undergo coronary stenting (March 2017)
• Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication
  View in Chinese
  • Direct oral anticoagulant drugs
  • Summary and recommendations
• Protein S deficiency
  View in Chinese
  • Timing of testing and effect of anticoagulants
  • Summary and Recommendations
• Risk and prevention of venous thromboembolism in adults with cancer
  View in Chinese
  • Hospitalized medical patients
  • Summary and recommendations
• Renal vein thrombosis and hypercoagulable state in nephrotic syndrome
  View in Chinese
  • Choice of anticoagulant
  • Anticoagulation for a thromboembolic event
  • Summary and recommendations
• Medical complications of stroke
  View in Chinese
  • Anticoagulants
  • Summary and recommendations
• Heparin and LMW heparin: Dosing and adverse effects
  View in Chinese
  • Transitioning between anticoagulants
  • Summary and recommendations
• Medical consultation for patients with hip fracture
  View in Chinese
  • Direct thrombin inhibitors and direct factor Xa inhibitors
  • Summary and recommendations
• The approach to the patient who refuses blood transfusion
  • Reversal of anticoagulation
  • Summary and recommendations
• Geriatric trauma: Initial evaluation and management
  View in Chinese
  • Patients taking anticoagulants
  • Summary and recommendations
• Low molecular weight heparin for venous thromboembolic disease
  View in Chinese
  • LMW heparin versus newer oral anticoagulants
  • Summary

Topic Outline Hide Topic Outline Show Graphics (0)